Compare 8x8 Inc (EGHT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Illumina, Inc. — how do they compare? 8x8 Inc trades at $2.04 (market cap $309.09M), while Illumina, Inc. trades at $190.55 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 94.2× 8x8 Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | ILMN | |
|---|---|---|
Market Cap | $309.09M | $29.12B |
Sector | Technology | Health |
52-Week High | $2.76 | $205.10 |
52-Week Low | $1.59 | $91.00 |
Enterprise Value | $576.02M | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.06, down 8.04% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with five consecutive quarters of revenue growth and consistent earnings beats, though profitability remains thin with a 0.64% net margin. Recent AI product expansions and partner program launches signal strategic growth initiatives. Analyst consensus targets $3.13, representing 52% upside potential from current levels.
EGHT presents a compelling risk-reward profile with significant analyst upside but faces execution risks in a competitive communications sector. The transition to profitability in 2026 forecasts and strong institutional support offset near-term volatility concerns. Key risks include high debt levels and margin pressure, while AI adoption growth and consistent earnings outperformance provide catalysts for valuation expansion.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
